{"symbol": "STML", "name": "Stemline Therapeutics", "next_earnings_utc": 1591956000, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1593475200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 12098430.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.45, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "stemline.com", "year_founded": 2003, "street_address": "750 Lexington Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "646 502 2311", "short_description": "Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe.", "long_description": "Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is headquartered in New York, New York.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 571992501, "total_enterprise": 420825912, "number_of_employees": 100, "outstanding_shares": 48147517, "eps": -1.584499, "diluted_eps": -1.584499, "earnings_from_cont_operations": -70703464, "gross_profit": -3721596, "cash": 152280657, "total_debt": 1114068, "total_revenue": 47040906, "cash_from_operations": -59326420, "net_income": -70703464, "ebitda": -73071125, "year_low_stock_price": 3.21, "year_high_stock_price": 18.22, "seekingalpha_follower_count": 5181, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/STML.png"}